GlassScriptPhysician profile
Allen C Williamson
NPI 1548269566
$6,093.91
in general payments reported to CMS, 2019-2025
40 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $850 · 2021: $1,595 · 2022: $1,253 · 2023: $1,046 · 2024: $446 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.08 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,157.44 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,021.26 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $396.76 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $391.04 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $348.11 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $344.26 | 2019-2022 | |
| Amarin Pharma, INC. | $334.64 | 2020-2022 | |
| Lilly USA, LLC | $280.73 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $196.28 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $180.45 | 2020-2022 | |
| Smith+Nephew, INC. | $138.35 | 2019-2020 | |
| Dexcom, INC. | $136.74 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $127.31 | 2021-2022 | |
| Allergan, INC. | $101.71 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $98.24 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.